|
|||||
|
|
Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases |
|
| Institution: | Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China |
| Abstract: | ObjectiveOsimertinib is a third-generation, irreversible, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that can effectively penetrate the blood brain-barrier (BBB). This study mainly explored the factors affecting the prognosis of EGFR-mutant advanced non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM), and whether osimertinib could improve the survival benefit in these patients compared with those not treated with osimertinib.MethodsWe retrospectively analyzed patients who had been admitted with EGFR-mutant NSCLC and cytologically confirmed LM to the Peking Union Medical College Hospital between January 2013 and December 2019. Overall survival (OS) was defined as the primary outcome of interest.ResultsA total of 71 patients with LM were included in this analysis, with a median OS (mOS) of 10.7 months (95% CI 7.6, 13.8]). Among them, 39 patients were treated with osimertinib after LM while 32 patients were untreated. Patients treated with osimertinib had a mOS of 11.3 months (95%CI 0, 23.9]) compared with the untreated patients who had a mOS of 8.1 months (95%CI 2.9, 13.3]), with a significant difference between the groups (hazard ratio HR]): 0.43, 95%CI:0.22–0.66, p = 0.0009). Multivariate analysis revealed the use of osimertinib were correlated with superior OS with a HR of 0.43 (95%CI 0.25, 0.75]), with a statistically significant difference (p = 0.003).ConclusionsOsimertinib can prolong the overall survival of EGFR-mutant NSCLC patients with LM and improve patient outcomes. |
| Keywords: | ARMS"} {"#name":"keyword" "$":{"id":"pc_KkkxeqaLWV"} "$$":[{"#name":"text" "_":"amplification-refractory mutation system BBB"} {"#name":"keyword" "$":{"id":"pc_joIZ2ovvdN"} "$$":[{"#name":"text" "_":"blood brain-barrier BM"} {"#name":"keyword" "$":{"id":"pc_eCrVMHhUi3"} "$$":[{"#name":"text" "_":"brain metastasis CI"} {"#name":"keyword" "$":{"id":"pc_33cOcwgc7F"} "$$":[{"#name":"text" "_":"confidence interval CNS"} {"#name":"keyword" "$":{"id":"pc_T2KNYVA3sW"} "$$":[{"#name":"text" "_":"central nervous system CSF"} {"#name":"keyword" "$":{"id":"pc_zfUCQKTEZw"} "$$":[{"#name":"text" "_":"cerebrospinal fluid EGFR"} {"#name":"keyword" "$":{"id":"pc_rwbMGJLpQz"} "$$":[{"#name":"text" "_":"epidermal growth factor receptor FFPE"} {"#name":"keyword" "$":{"id":"pc_IVDiPRGbdL"} "$$":[{"#name":"text" "_":"formalin-fixed paraffin-embedded HR"} {"#name":"keyword" "$":{"id":"pc_JqXF0DNbDE"} "$$":[{"#name":"text" "_":"hazard ratio ICIs"} {"#name":"keyword" "$":{"id":"pc_Slx98ZJ0h2"} "$$":[{"#name":"text" "_":"immune checkpoint inhibitors LM"} {"#name":"keyword" "$":{"id":"pc_v4pyp1S71L"} "$$":[{"#name":"text" "_":"leptomeningeal metastases NSCLC"} {"#name":"keyword" "$":{"id":"pc_SOMZpY3YJ3"} "$$":[{"#name":"text" "_":"non-small cell lung cancer OS"} {"#name":"keyword" "$":{"id":"pc_gsWUmNiJc2"} "$$":[{"#name":"text" "_":"overall survival PUMCH"} {"#name":"keyword" "$":{"id":"pc_xU6AmPyLrt"} "$$":[{"#name":"text" "_":"Peking Union Medical College Hospital TKI"} {"#name":"keyword" "$":{"id":"pc_4OFBcxDoAb"} "$$":[{"#name":"text" "_":"tyrosine kinase inhibitor WBRT"} {"#name":"keyword" "$":{"id":"pc_YsdRzrt0a3"} "$$":[{"#name":"text" "_":"whole-brain radiotherapy |
| 本文献已被 ScienceDirect 等数据库收录！ | |